Technical Analysis for VTGN - VistaGen Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
VTGN closed up 1.2 percent on Friday, January 18, 2019, on 67 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
|Weak or Absent||Up||Down||Down|
|See historical VTGN trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Hammer Candlestick||Bullish||0.00%|
|Jan 18||Pocket Pivot||Bullish Swing Setup||0.00%|
|Jan 18||Doji - Bullish?||Reversal||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 17||Wide Bands||Range Expansion||1.20%|
|Jan 16||50 DMA Resistance||Bearish||-1.18%|
|Jan 16||Narrow Range Bar||Range Contraction||-1.18%|
|Jan 16||NR7||Range Contraction||-1.18%|
|Jan 16||Inside Day||Range Contraction||-1.18%|
|Jan 16||Wide Bands||Range Expansion||-1.18%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more VTGN news...
|52 Week High||2.44|
|52 Week Low||0.81|
|200-Day Moving Average||1.462|
|50-Day Moving Average||1.6969|
|20-Day Moving Average||1.573|
|10-Day Moving Average||1.699|
|Average True Range||0.1149|
|Chandelier Exit (Long, 3 ATRs )||1.5053|
|Chandelier Exit (Short, 3 ATRs )||1.6047|
|Upper Bollinger Band||1.8697|
|Lower Bollinger Band||1.2763|
|Percent B (%b)||0.68|
|MACD Signal Line||-0.0026|
|Market Cap||15.75 Million|
|Num Shares||9.38 Million|
|Price-to-Earnings (P/E) Ratio||-1.24|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||1.83|
|Resistance 3 (R3)||1.81||1.75||1.81|
|Resistance 2 (R2)||1.75||1.71||1.76||1.80|
|Resistance 1 (R1)||1.71||1.68||1.73||1.73||1.79|
|Support 1 (S1)||1.61||1.61||1.63||1.63||1.57|
|Support 2 (S2)||1.55||1.58||1.56||1.56|
|Support 3 (S3)||1.51||1.55||1.56|
|Support 4 (S4)||1.53|